Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a Study of HIV Entry Inhibitor CPT31 in Healthy Adults
NCT04672083Phase 1Completed
- Sponsor
- Navigen Pharmaceuticals
- Start
- Nov 2020
- Primary completion
- Apr 2021
- Modality
- Modified Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cholesterol-PIE12-trimer in human immunodeficiency virus infection (HIV) (4 cohorts), sponsored by Navigen Pharmaceuticals. Primary endpoint: Adverse Events. Started Nov 2020; status: completed.
02
Drugs
cholesterol-PIE12-trimer
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04672083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04672083.